Introduction
Upregulation of cyclooxygenase 2 (COX-2) has been observed in various cancers and pre-malignant tissues, and considerable evidence demonstrates that COX-2 contributes to the tumorigenesis of many tissue types (Williams et al., 1999; Prescott and Fitzpatrick, 2000; Howe and Dannenberg, 2002; Subbaramaiah and Dannenberg, 2002; Trifan and Hla, 2003) . For example, transgenic overexpression of COX-2 was able to induce tumor formation in the mammary gland (Liu et al., 2001) ; knocking out the COX-2 gene in the APC 716 mouse (a mouse model of human familial adenomatous polyposis) reduced the number and size of intestinal polyps (Oshima et al., 1996) ; inhibition of COX-2 by pharmacological agents also suppressed intestinal polyps (Lal et al., 2001) ; and COX-2 knockout mice developed 75% fewer chemically induced skin papillomas than control mice (Tiano et al, 2002) . COX-2 inhibition has been adopted in humans as a preventive measure for the population of high risk for colon cancer, the familial adenomatous polyposis mutation carriers, with impressive success (Steinbach et al., 2000) . Generally, COX-2 expression is thought to increase proliferation Trifan and Hla, 2003) , promote survival (Moore and Simmons, 2000; Munkarah et al., 2002; Trifan and Hla, 2003) , and stimulate angiogenesis (Masferrer et al., 2000; Masferrer, 2001 ; Leahy et al., 2002) , although these mechanisms are not satisfactorily explained by the in vivo findings (Williams et al., 2000; Trifan and Hla, 2003) .
In ovarian cancer, though COX-2 has also been considered as a potential target for chemoprevention and anti-cancer therapy (Cramer et al., 1998; Akhmedkhanov et al., 2001; Nasi and Castiglione, 2002; Rodriguez-Burford et al., 2002; Sorensen et al., 2003) , whether COX-2 is overexpressed in tumors is controversial. Several studies reported the expression of COX-2 in ovarian tumors based on immunostaining (Dore et al., 1998; Klimp et al., 2001; Matsumoto et al., 2001; Denkert et al., 2002; Ferrandina et al., 2002; Shigemasa et al., 2003) ; however, recent studies suggested that COX-2 is not frequently expressed in ovarian cancer (Gupta et al., 2003; Roland et al., 2003) . We found that COX-2 is often expressed in preneoplastic lesions and normal ovarian surface and inclusion cyst epithelia, but it is not normally detected in established ovarian cancer (Roland et al., 2003) . It was proposed that COX-2 expression may promote ovarian preneoplastic transformation and underlie the link between the etiological factor of ovulation and ovarian cancer risk (Smith et al., 2004) . Nevertheless, a role for COX-2 expression in established ovarian tumors is not certain.
A physiological role of COX-2 in ovulation is quite clear: following gonadotropin stimulation, a surge of COX-2 expression in the ovary is induced prior to ovulation (Espey, 1994; Tsafriri and Reich, 1999; Duffy and Stouffer, 2001; Tokuyama et al., 2001; Richards et al., 2002) . Additionally, studies using either gene knockout or enzymatic inhibitors indicate that COX-2 activity is required for ovulation (Downs and Longo, 1982; Okamura et al., 1985; Lim et al., 1997; Davis et al., 1999; Norman, 2001; Pall et al., 2001) . Tumor necrosis factor alpha (TNF-a), a proinflammatory cytokine, is a putative physiological regulator of COX-2 expression in the ovary (Brannstrom et al., 1995; Murdoch et al., 1997; Terranova and Rice, 1997) . TNF-a is rich in the ovary and has been implicated as a local mediator of gonadotropin-stimulated ovulation (Brannstrom et al., 1995; Murdoch et al., 1997; Terranova and Rice, 1997) .
COX-2 is an immediate-early gene in mitogenic and cytokine responses and the COX-2 promoter contains sequences for binding of NF-kB, PEA3, and AP-1 transcription complexes (Subbaramaiah and Dannenberg, 2002; Chun and Surh, 2004) . TNF-a is known to activate several cellular signaling pathways (Baud and Karin, 2001; Chen and Goeddel, 2002; Wang and ElDeiry, 2003) , which mediate the expression of COX-2 by facilitating the recruiting of various transcription factors to the COX-2 promoter (Subbaramaiah and Dannenberg, 2002; Chun and Surh, 2004) . In many cell types, COX-2 expression appears to be regulated by mitogen-activated protein kinase (MAPK) signal pathways (Subbaramaiah and Dannenberg, 2002; Chun and Surh, 2004) . The MAPK superfamily is mainly made up of three kinase members, including p38MAPK, extracellular signal-regulated kinases (ERKs) p44MAP-K(ERK1) and p42MAPK(ERK2), and c-jun NH 2 terminal kinase (JNK), which consists of p45 JNK1 and p54 JNK2 (Boulton et al., 1991) . Activation of NF-kB and PI3 Kinase/AKT pathway has also been shown to regulate COX-2 expression (Subbaramaiah and Dannenberg, 2002; Chun and Surh, 2004) .
To resolve the issue about the expression of COX-2 in ovarian cancer, we investigated COX-2 expression and regulation, comparing noncancerous ovarian surface epithelial and cancer cells.
Results

COX-2 expression in primary and nontumorigeneic ovarian surface epithelial cells and stimulation by TNF-a
Although increased COX-2 expression was often observed in preneoplastic ovarian surface epithelium (Roland et al., 2003) , the direct stimulator of COX-2 expression was not yet established. Reproductive hormones and local mediators of ovulation are likely candidates to regulate COX-2 expression. In the present study, gonadotropins including follicle stimulating hormones (FSH) and luteinizing hormone (LH), cytokines including TNF-a and interleukin (IL)-1b, and the À8 M) and LH (10 À8 M), androgen (3 nM), IL-1b (10 ng/ml), or TNF-a (10 ng/ml) for 24 h. COX-2 protein expression was analysed by Western blotting. (c) Primary ovarian surface epithelial cells were either not treated (Control) or treated with gonadotropins including FSH (10 À8 M) and LH (10 À8 M), androgen (3 nM), or TNF-a (10 ng/ml) for 24 h. Total RNA was isolated for RT-PCR to determine COX-2 mRNA level. The b-actin signal was used as a control for the amount of total RNA used. (d) Primary ovarian surface epithelial cells were treated with an increasing amount of TNF-a (1-100 ng/ml) for 6 h, or (e) were treated with TNF-a (10 ng/ml) for the indicated period of time (0-24 h). COX-2 protein expression was analysed by Western blotting. (f) Ovarian surface epithelial cells, HIO-80 and HIO-105, were treated with an increasing amount of TNF-a (0.1-10 ng/ml) for 6 h. COX-1 protein expression was analysed by Western blotting principal LH-induced sex hormone in growing follicles and putative local mediator of ovulation, androgen, were tested for their effect on COX-2 expression in ovarian surface epithelial cells. Two preparations of primary human ovarian surface epithelial cells and three lines of human 'immortalized' ovarian surface epithelial cells were used in this study. The proliferative lifespan of the HIO cells in culture is prolonged by transfection with SV40 antigen. These cells normally express a minimal but detectable amount of COX-2. Although the transformation with SV40 antigen allows us to produce sufficient cells with ovarian surface epithelial properties for study, the transformation and continuing passages likely cause changes in some aspects related to cell cycle control of the cells.
To a similar extent in all these cells, as shown in two representative examples using primary ovarian surface epithelial cells (Figure 1a ) or HIO-105 (Figure 1b ), TNF-a and interleukin 1-beta (IL-1b) treatment markedly induced COX-2 expression, whereas gonadotropins and androgen had no effect. An increase of COX-2 mRNA as determined by RT-PCR was observed following TNF-a stimulation of primary cells (Figure 1c ), indicating the regulation at the mRNA level. The time-and dose-dependent TNF-a stimulation of COX-2 expression was investigated. As shown in Figure 1d , TNF-a increased COX-2 expression in a concentration-dependent manner from 1 to 100 ng/ml during a 6 h incubation. An increase in COX-2 protein was detected 1 h after treatment. The level of COX-2 protein continued to increase with a peak response observed at 19 h of treatment and leveled off between 19 and 24 h (Figure 1e ). Similar results were obtained in two cell preparations and three nontumorigenic HIO lines .
In the primary or 'immortalized' human ovarian surface epithelial cells, COX-1 expression was weakly detected. Unlike COX-2, COX-1 protein levels were not significantly stimulated by TNF-a treatment (Figure 1f ).
TNF-a induces activation of NF-kB, AKT, and MAP kinase signal pathways and their involvement in COX-2 expression in ovarian surface epithelial cells
To investigate TNF-a-activated signaling pathways that contribute to the regulation of COX-2 expression, we first examined effects of TNF-a treatment on the activation of several principal cellular signal pathways. As shown in an example in Figure 2a , TNF-a caused an acute activation of p38MAPK, JNK, ERK, and PI3 kinase/AKT pathways. Activation of p38MAPK was observed at 5 min after treatment, reached its highest level at 15 min, and receded by 60 min. Activation of JNK peaked at 15 min. Activated forms of ERK1/2 and AKT were present in HIO-80 cells under basal conditions, and a slight increase was detected 15 min after treatment. TNF-induced AKT activation was observed 15 min after treatment and remained elevated during a 60-min time course (Figure 2a) . NF-kB is normally sequestered in the cytoplasm by an inhibitor protein, designated I-kB. Cellular activation Figure 2 TNF-a-activated signaling pathways contributing to COX-2 expression in ovarian surface epithelial cells. (a) HIO-80 ovarian surface epithelial cells were exposed to 10 ng/ml TNF-a for the indicated time. Cells were lysed for Western blot analysis using antibodies specific for the phosphorylated forms of p38, JNK, p42/44 ERKs, and AKT. (b) HIO-80 and HIO-114 cells were treated with TNF-a for either 20 or 60 min. Cytoplasmic and nuclear proteins were isolated as indicated in 'Materials and methods' and analysed for NF-kB (p65) expression at each time point by Western blot. The actin protein level was also analysed as a loading control. (c) HIO-80 cells were preincubated with U0126 (1 mM), SP600125 (1 mM), SB203580 (1 mM), TLCK (50 mM), LY294002 (20 mM) or vehicle control for 1 h before treatment with TNF-a (10 ng/ml) for another 6 h. Whole-cell lysates were prepared to analyse COX-2 protein expression by Western blotting. The actin protein level was also analysed as a loading control. Similar results were obtained from another two independent experiments Loss of COX-2 expression in ovarian cancer cells W-L Yang et al leads to the phosphorylation-dependent degradation of I-kB, accompanied by the translocation of free NF-kB to the nucleus, where it binds to consensus sequences in the promoter region of target genes and activates transcription (Ghosh and Baltimore, 1990; Hsu et al., 1995; Baldwin, 1996; Barnes and Karin, 1997) . In the present study, the activation of NF-kB was assessed by its nuclear localization. Both nuclear and cytoplasmic proteins were prepared at 20 and 60 min after TNF-a treatment and the level of NF-kB (p65) was analysed by Western blot. As shown in Figure 2b , the amount of NF-kB protein in the nuclear fraction is negligible in unstimulated cells. Stimulation of cells with TNF-a for 20 min resulted in a marked increase in NF-kB (p65) protein, which then returned nearly to the basal level by 60 min after stimulation. The amount of NF-kB (p65) protein remained constant in the cytoplasmic fraction. The pattern of NF-kB activation by TNF-a in the noncancer ovarian surface epithelial cells was confirmed by an additional assay that measured the binding of p65 to oligonucleotides with an NF-kB binding sequence (see below, Figure 6 ). Results from these studies demonstrate that TNF-a is able to activate p38MAPK, JNK, ERK1/2, and AKT pathways as well as NF-kB activity in ovarian surface epithelial cells.
To determine the contribution of these signaling pathways to TNF-a-induced COX-2 expression, the effects of inhibitors for these pathways on COX-2 expression were investigated. LY294002 (PI3 kinase inhibitor), SB203580 (p38MAPK inhibitor), SP600125 (JNK inhibitor), UO126 (MEK1 inhibitor), and TLCK (NF-kB inhibitor) were used to dissect the signaling pathways involved in TNF-a-stimulated COX-2 expression. Human ovarian surface epithelial cells were pretreated with each inhibitor 1 h before incubation with TNF-a for another 6 h. As shown in Figure 2c , treatment either with LY294002, U0126, SP600125, or TLCK caused a 75-80% inhibition of TNF-induced COX-2 protein expression, while a 50% inhibition was detected in SB203580-treated cells. Similar results were obtained in other nontumorigenic ovarian surface epithelial cells. Results from this study suggest that activation of JNK, ERK1/2, p38MAPK, AKT, and NFkB contribute to TNF-a-induced COX-2 expression in ovarian surface epithelial cells.
Lack of COX-2 induction by TNF-a in ovarian cancer cells
In contrast to cancers of other organ sites, ovarian tumors and most ovarian cancer cell lines are negative for COX-2 expression (Gupta et al., 2003; Roland et al., 2003) . We analysed the expression of COX-2 and its regulation in five ovarian cancer cell lines: A2780, OVCAR4, OVCAR8, and OVCAR10 are COX-2 negative, and OVCAR5 is positive for COX-2. This panel of cancer cell lines represents the frequency of COX-2 expression in ovarian tumors, which are mostly negative and are positive only in less than 10% of the tumors analysed (Roland et al., 2003) . , and OVCAR5 were treated with TNF-a (10 ng/ml) for 6 h. Cells were harvested to analyse COX-1 and COX-2 protein expression by Western blot. The actin protein level was also analysed as a loading control. (c) Summarized data derived from three independent Western blotting experiments represents time course of TNF-a (10 ng/ml) stimulated COX-2 expression. The COX-2 signals in Western blots were normalized by b-actin signals and compared using arbitrary units. (d) Summarized data on COX-2 expression derived from three to six independent Western blotting experiments from each cell lines stimulated with or without TNF-a (10 ng/ml) for 6 h. The COX-2 signals in Western blots were normalized by b-actin signals and compared using arbitrary units. A statistical difference between with or without TNF-a stimulation was analysed by Student's t-test: *Po0.01
We next determined whether TNF-a is able to increase COX-2 protein expression in ovarian cancer cells. OVCAR4 cells were treated with increasing concentrations of TNF-a from 0.1 to 20 ng/ml for 6 h. Cells were harvested to analyse both COX-1 and COX-2 protein expression by Western blot. COX-1 was constitutively expressed in OVCAR4 cells, and its expression was not significantly affected by TNF-a treatment (Figure 3a) . The immunoreactivity for COX-1 appeared as a doublet, which has been previously observed by others (Fong et al., 2000; Singer et al., 2003) . We did not detect significant expression of COX-2 protein in OVCAR4 cells at any given dose of TNF-a (Figure 3a) . Although sometime a weak signal of COX-2 can be observed upon prolonged exposure as seen in the example in Figure 3a , in the cells stimulated with 10 ng/ml of TNF-a. Nevertheless, the COX-2 expression in A2780, OVCAR4, OVCAR8, and OVCAR10 cells was insignificant over a time of TNF-a stimulation comparing with noncancer cells (Figure 3b ), as summarized in Figure 3c , d, that represent a number of repeated experiments.
Thus, induction of COX-2 expression by TNF-a was only detected in OVCAR5 but not in A2780, OVCAR4, OVCAR8, and OVCAR10 cells, suggesting that the majority of ovarian cancer cells are refractory to TNFa-induction of COX-2 expression (Figure 3d ).
Altered response of COX-2 expression to TNF-a-stimulated signal pathways in OVCAR5 cells
As OVCAR5 is the only ovarian cancer cell line tested that still maintains TNF-a-induced COX-2 expression, it was of interest to investigate whether the cell line utilizes MAPK, AKT and NF-kB pathways to mediate TNF-ainduced COX-2 expression, as was found in the noncancerous cells. OVCAR5 cells were stimulated with TNF-a and the activation of MAPK and AKT signaling pathways was determined by Western blotting using phospho-specific antibodies. As shown in Figure 4a , activation of p38MAPK reached its highest level between 5 and 15 min, and returned to near basal level between 30 and 60 min. TNF-a-stimulated activation of ERK1/2 reached a maximal level at 15 min and returned to basal levels between 30 and 60 min. Activation of JNK was detected between 5 and 15 min, and returned to basal level by 30 min. Activation of AKT was detected before stimulation; however, TNF-a treatment did not further enhance its activation. TNF-a also activated the NF-kB pathway in OVCAR5 cells ( Figure 6 , see text below). Thus, similar TNF-astimulated signaling pathways were observed in OV-CAR5 and in nontumorigenic ovarian surface epithelial cells (Figure 2) .
The contribution of these signaling pathways in TNFa-induced COX-2 expression was examined using the same battery of inhibitors. Surprisingly, TNF-a-induced COX-2 expression is resistant to the suppression by the inhibitors. COX-2 expression can only be reduced slightly by the inhibition of the AKT pathway using LY294002, and no effect or sometimes a slight increase in COX-2 protein level was observed when OVCAR5 cells were treated with inhibitors to suppress p38MAPK, ERK1/2, JNK and NF-kB pathways (Figure 4b ). Given that TNF-a is unable to enhance the basal level of AKT activity, reduction of TNF-a-induced COX-2 expression by LY294002 indicates that the basal activity of AKT is important for inducible expression of COX-2. Lack of inhibitory effect of inhibitors for NF-kB and MAPK kinases suggests that TNF-a-induced COX-2 expression in OVCAR5 cells is no longer individually dependent on the activation of p38MAPK, ERK1/2, JNK, or NF-kB pathways.
TNF-a-induced signal pathways in ovarian cancer cells
Loss of TNF-a-induced COX-2 protein expression in the majority of ovarian cancer cell lines tested, including A2780, OVCAR4, OVCAR8, and OVCAR10, raised the possibility that the TNF-a-activated signaling pathways are altered in these cancer cell lines. Thus, the effects of TNF-a treatment on the signal pathways were investigated in these cancer cells. Generally, we found that TNF-a is able to stimulate the principle signaling pathways in all of these five cancer cell lines, with some An example is shown in Figure 5a for A2780 cells, in which phospho-AKT is undetectable before or after stimulation. TNF-a failed to induce activation of the p54 form of JNK although it still manifested a weak induction of the p46 form of JNK. ERK1/2 are constitutively activated and is not affected by TNF-a The ability of TNF-a to induce NF-kB activation in ovarian cancer cells, OVCAR4, OVCAR5, OVCAR8, and A2780, was again assessed by its nuclear localization and binding to the consensus binding sequences. Following stimulation for 20 and 60 min, both nuclear and cytoplasmic proteins were prepared and the level of NF-kB (p65) was analysed by Western blot. As shown in Figure 6a , and similarly in all the cancer cells, TNF-a induces nuclear translocation of NF-kB (p65) protein.
In these cancer cells, nuclear NF-kB (p65) protein remains high after stimulation rather than downregulated by 60 min as in nontumorigenic ovarian surface epithelial cells (Figure 2b) . To confirm the TNF-astimulated increase in NF-kB nuclear localization corresponded to its DNA-binding activity, nuclear proteins extracted from treated and untreated cells were analysed by ELISA-based DNA binding assay using a double-stranded oligonucleotide containing the consensus NF-kB binding sequences. As shown in Figure 6b , NF-kB DNA-binding activity was not detected in nonstimulated HIO-80 or HIO-114 cells. A significant increase in NF-kB binding activity was observed at 20 min after TNF-a stimulation and returned to nearly basal level by 60 min. The specificity of DNA binding was confirmed by a competition assay, where excess of free NF-kB oligonucleotides (1 mg) was added into the reaction and shown to obliterate NF-kB DNA binding activity (Figure 6b) .
In contrast to the nontumorigenic ovarian surface epithelial (OSE) cells, in ovarian cancer cells TNF-ainduced NF-kB binding activity persists 60 min after treatment (Figure 6b ), which likely is a result of the TNF-a-induced prolonged nuclear localization of NFkB (p65) (Figure 6a ). Thus, it appears that NF-kB activation is enhanced in both magnitude and duration in cancer cells compared to nontumorigenic OSE cells. Apparently, the principle TNF-a-stimulated signaling pathways are mostly intact or even enhanced in ovarian cancer cells. Results from these experiments indicate that the loss of TNF-a-induced COX-2 expression in ovarian cancer cells is unlikely due to defective activation of NF-kB, MAPK, and AKT pathways.
Close association between loss of COX-2 expression and epithelial neoplastic morphological transformation
Previously, we have determined that COX-2 expression is often absent in human ovarian cancer tissues (Liu et al., 2001) . We further investigated the correlation between the losses of COX-2 with alterations of ovarian epithelial morphology. In the portion of ovarian cancer confined to the ovaries, we were able to identify monolayer epithelial cells: the remains of surface or inclusion cyst epithelia. In some cases, these monolayer epithelial cells are linked contiguously to neoplastic lesions (Yang et al., 2002) . We have found contiguous epithelial transitions in 28 cases of grade II and III ovarian serous adenocarcinomas following examination of about 300 ovarian tumor blocks (Yang et al., 2002) . Seven of these ovarian serous carcinomas containing contiguous links between monolayer epithelial and neoplastic cells identified previously were used for analysis of COX-2 expression. In monolayer epithelium, COX-2 staining is often weakly positive, as shown in an example in Figure 7a . COX-2 is often highly positive in preneoplastic lesions as reported previously (Roland Figure 7d) , and the staining is absent in adjacent neoplastic cells. The COX-2 staining of an ovarian surface epithelial papillae structure (Figure 7e) can be competed by a competing antigen peptide (Figure 7f ), indicating the specificity of the COX-2 staining. Thus, the loss of COX-2 expression in ovarian cancer cells appears to associate with the transition of monolayer epithelial cells to overt neoplastic lesions.
Discussion
In the current study, we demonstrate that the proinflammatory cytokine TNF-a is capable of stimulating the expression of COX-2 protein in noncancerous ovarian surface epithelial cells. TNF-a stimulates COX-2 expression by activating p38MAPK, JNK, Erk1/2, AKT, and NF-kB pathways, and the collaboration of all these pathways is required for efficient stimulation of COX-2 expression. It is likely these signaling pathways activate COX-2 expression through the NF-kB and AP-1 elements that are present in the COX-2 promoter (Subbaramaiah and Dannenberg, 2002; Chun and Surh, 2004) . However, TNF-a fails to elicit COX-2 expression in four out of five ovarian cancer cell lines tested. OVCAR-5 is the only ovarian cancer cell line in which TNF-a is able to stimulate COX-2 expression. In OVCAR-5 cells, inhibition of AKT pathway only slightly reduces, and inhibition of other pathways fails to suppress, the TNF-a-stimulated COX-2 expression, suggesting the regulation of COX-2 expression is altered and is no longer dependent on the combination of Erks, p38MAPK, JNK, AKT, and NFkB signaling pathways. In ovarian tumor sections containing contiguous transitions between monolayer epithelial and neoplastic cells, we found that the loss of COX-2 occurs when the monolayer epithelial cells undergo morphological transformation into neoplastic lesion.
The current study further verifies that COX-2 is not commonly overexpressed in ovarian cancer cells, and that COX-2 expression is no longer responsive to the cellular signaling pathways that are activated by mitogens and cytokines such as TNF-a. TNF-a is one of the most pleiotropic cytokines that act as host defense factors in immunological and inflammatory responses (Old, 1985; Baud and Karin, 2001 ). It was also described as an agent causing hemorrhagic necrosis of transplanted murine sarcoma (Komori et al., 1993) . TNF-a causes cell death by activating the apoptotic program through the recruitment of adaptors TRADD and FADD, and subsequently caspase 8, to the receptor TNFR1 (Hsu et al., 1995; Baud and Karin, 2001 ; Chen Goeddel, 2002) . In addition to acting as an antitumor reagent, TNF-a also plays pivotal roles in the angiogenesis, growth, invasion, and metastases of certain neoplasms (Old, 1985; Komori et al., 1993; Nabors et al., 2003) . The basis for the opposing effects of TNF-a on tumor cells may be the diverse signaling pathways it elicits: the FADD, p38MAPK, and JNK pathways are proapoptotic, and the ERK1/2, AKT, and NF-kB pathways favor cell survival and proliferation (Hsu et al., 1995) . Recent gene knockout studies provide further support that the TNF-a pathway is involved in promotion and progression of premalignant cells: either TNF-a null (Moore et al., 1999; Suganuma et al., 1999) or receptor deficient (Arnott et al., 2004) mice are resistant to the development of carcinogen-induced skin cancer.
In ovarian cancer etiology, TNF-a-mediated inflammation has been proposed to contribute to cancer risk (Ness and Cottreau, 2000; Yang et al., 2004) . Consistent with this idea, TNF-a is able to stimulate expression of COX-2 in nontumorigenic ovarian surface epithelial cells. COX-2 expression is common in preneoplastic ovarian epithelial lesions (Roland et al., 2003) and is proposed to contribute to epithelial cell transformation as a mechanism underlying ovulation as a risk factor for ovarian cancer (Smith et al., 2004) . In established tumors, the proapoptotic pathways are commonly suppressed, and these pathways presumably are inactivated in ovarian cancer cells. The remaining TNF-aactivated pathways likely contribute to neoplastic growth, and thus converting TNF-a to become a tumor promoter (Malik et al., 1989) and to have a role in metastasis (Malik et al., 1990) . Our finding that TNF-a activates the NF-kB pathway in both magnitude and duration in all the ovarian cancer cells tested is consistent with the idea that TNF-a activates a tumorpromoting pathway. Among the TNF-a regulated pathways and target genes in ovarian cancer cells, a consistent finding in ovarian cancer cells is that COX-2 expression is silenced and uncoupled from the regulation by TNF-a and the associated cellular signaling pathways.
In contrast to other malignancies, established ovarian tumor cells are commonly negative for COX-2 expression, and TNF-a is no longer able to induce COX-2 expression in the cells. A remaining question is whether the loss of TNF-a-stimulated COX-2 expression contributes to malignancy and progression of ovarian tumors, or if it is just an associated event. Why the ovarian cancer cells inactivate their COX-2 expression is difficult to explain since COX-2 expression is currently thought to contribute to tumor cell proliferation, survival, and angiogenesis (Williams et al., 1999; Prescott and Fitzpatrick, 2000; Howe and Dannenberg, 2002; Subbaramaiah and Dannenberg, 2002; Trifan and Hla, 2003) . It is possible that the loss of COX-2 and its inducible expression by TNF-a may enable the ovarian tumor cells to reduce inflammation and escape immune surveillance. Another possibility is that ovarian tumor cells may contain enzymes that convert COX-2-catalysed arachidonic acid metabolites to alternative prostaglandins and thromboxanes, which are incompatible with tumor progression. Prostaglandin H 2 (PGH 2 ), the product of COX-2-catalysed reaction, is further converted to a variety of prostaglandins and thromboxanes by various isomerases that are expressed in specific cell types and tissues. It is possible that the ovarian specific isomerase may produce metabolites with activity unfavorable for the growth of ovarian cancer cells.
A recent study reports that in ovarian cancer, COX-1 instead of COX-2 is over-expressed (Gupta et al., 2003) . In ovaries, the expression of COX-1 can compensate for COX-2 function. It was found that, in contrast to the initial finding (Lim et al., 1997) , the COX-2 knockout is reproductively adequate in females in certain genetic backgrounds due to a compensatory upregulation of COX-1 (Wang et al., 2004) . Although COX-1 and COX-2 expression in ovaries is predominately in follicles and granulosa cells, rather than surface epithelial cells (Wang et al., 2004) , it is possible that the loss of COX-2 expression in cancer cells leads to a compensatory expression of COX-1. Nevertheless, we did not observe the induction by TNF-a of COX-1 in cancer or noncancer ovarian surface epithelial cells.
Since COX-2 is frequently expressed in the preneoplastic ovary and is believed to contribute to an early step of neoplastic transformation, COX-2 inhibitors may be useful for chemoprevention of early diseases. Our current investigation suggests that COX-2 expression and inducibility by TNF-a are lost in established tumor cells, thus this study raises questions about the general concept of a role for COX-2 expression in cancer progression and malignancy. , and LY294002 (AKT inhibitor) were purchased from Calbiochem (La Jolla, CA, USA). Actin antibody and Nk-p-Tosyl-Llysine chloromethyl ketone hydrochloride (TLCK, inhibitor for NF-kB) were purchased from Sigma (St Louis, MO, USA). Peroxidase-labeled goat anti-mouse IgG were purchased from Kirkegaard & Perry Laboratories (Gaithersburg, MD, USA). Peroxidase-labeled goat anti-rabbit IgG and Bio-Rad Dc Protein Assay Kit were obtained from Bio-Rad (Hercules, CA, USA). SuperSignal West Dura Extended Duration Substrate was purchased from Pierce (Rockford, IL, USA). Enzyme-linked immunosorbent assay (ELISA)-based transcription factor activity BD Mercury Transfactor kit for NFkB was purchased from BD Biosciences (Palo Alto, CA, USA). NE-PER Nuclear and Cytoplasmic Extraction Reagents were obtained from Pierce (Rockford, IL, USA). All other reagents, unless otherwise specified, were purchased from Sigma (St Louis, MO, USA).
Materials and methods
Materials
Cell culture
Primary ovarian surface epithelial (OSE) cells were prepared from prophylactic oophorectomies as previously described (Siemens and Auersperg, 1988; Roland et al., 2003) . Briefly, ovarian surface epithelial cells were scraped from the surface of the ovarian tissues and the cells were cultured in medium 199 and MCDB 105 (1 : 1) supplemented with 15% fetal bovine serum (FBS), 0.25 U/ml insulin, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin. Cells cultured between passages 2 and 4 were used for experiments. The immortalized nontumorigenic human OSE cells were generated by transfecting primary OSE cells with the SV40 large T antigen (Roland et al., 2003) . Three immortalized human ovarian surface epithelial cell lines, HIO-80, HIO-114, and HIO-105, were cultured in the same medium used for maintaining primary OSE cells. The ovarian cancer cell lines, OVCAR4, OVCAR5, OVCAR8, OVCAR-10, and A2780 (Hamilton et al., 1984; Schilder et al., 1990) , were cultured in RPMI 1640 supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin. The cultures were maintained in a humidified atmosphere of 95% air/5% CO 2 at 371C.
For experiments, cells were cultured in 60 mm plates until reaching 90% confluence, and then were switched to serumfree medium 24 h before treatment. For Western blot analysis, cells were lysed with RIPA buffer (150 mM NaCl, 1% sodium deoxycholate, 1% Triton X-100, 0.1% SDS, 10 mM Tris, pH 7.2, 100 mM sodium orthovanadate, 50 mM sodium fluoride) containing complete protease inhibitors (Boehringer Mannheim, Indianapolis, IN, USA). Lysates were centrifuged at 10 000 g for 10 min to remove particulate sediment. Protein concentration was measured using the Bio-Rad Dc protein assay.
Western blot analysis
Total cellular protein (30-50 mg) was subjected to electrophoresis on a 7.5% SDS polyacrylamide gel and electrotransferred onto PVDF membrane (Bio-Rad). After blocking with 5% nonfat dry milk in 10 mM Tris, pH 7.5, containing 0.15 M NaCl, 0.05% Triton X-100, the membranes were probed with primary antibodies. The membranes were then washed and incubated with the secondary antibody conjugated with horseradish peroxidase. Protein bands were visualized using the chemiluminescence detection system (SuperSignal West Dura Extended Duration Substrate).
ELISA-based transcription factor activity assay
Nuclear protein from ovarian cell lines was extracted using the NE-PER Nuclear and Cytoplasmic Extraction Reagents and quantified using the Bio-Rad Dc protein assay. The ELISA-based transcription factor activity assay was performed following the manufacturer's protocol. Briefly, 10 mg of nuclear extracts was incubated in 96-well plates coated with oligonucleotides containing the consensus binding sequences for either p65 NF-kB or a scrambled sequence as a control. Transcription factors that bound were then detected by the p65 antibody followed by a horseradish peroxidase-conjugated secondary antibody. After the colorimetric substrate was added, the enzymatic product was measured at OD 655 nm using an absorbance microplate reader. For competition assays, excess competitor oligonucleotides (1 mg) were coincubated with nuclear protein.
Ovarian tumor specimens and immunostaining
Archived human ovarian tumor tissues from Fox Chase Cancer Center and Emory University tumor bank were used for immunostaining. In this study, selected ovarian tumor tissues containing monolayer ovarian surface or cystic epithelia continuously linked with neoplastic lesions identified from a previous investigation were used (Yang et al., 2002) . The tissue paraffin blocks were cut into 5 mm sections and placed on positively charged glass slides. The sections were stained with anti-COX-2 following heat-induced antigen retrieval in 0.01 M sodium citrate buffer (pH 6.0). The detailed procedure used has been described previously (Roland et al., 2003) . Both a goat (clone C-20) antibody for COX-2 from Santa Cruz (Santa Cruz, CA, USA) and a rabbit polyclonal serum from Cayman (Ann Arbor, MI, USA) were used for immunostaining and gave similar results. An accompanying COX-2 peptide was tested and found to block staining, indicating the COX-2 immunostainings observed are specific.
Reverse transcription-PCR
Total RNA from primary ovarian surface epithelial cells was isolated with Trizol s Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Firststrand cDNA synthesis was performed on 0.5 mg total RNA using the random priming extension method. The reaction conditions were as follows: 10 min at room temperature, 30 min at 421C, 5 min at 951C and 5 min at 41C.
PCR primers were designed according to the published human cDNA sequences. The primer sequences were: COX-2 (sense), 5 0 -AAGCC TTCTC TAACC TCTCC-3 0 ; COX-2 (antisense), 5 0 -TAAGC ACATC GCATA CTCTG-3 0 ; b-actin (sense), 5 0 -GGACG ACATG GAGAA AATCT GG-3 0 ; bactin (antisense), 5 0 -GGATA GCAAC GTACA TGGCT GG-3 0 . The predicted size for the PCR products for each primer pairs was 531 bp for COX-2 and 171 bp for b-actin. PCR was initiated by adding the reverse transcription reaction product into the PCR reaction mix consisting of 20 mM Tris-HCl, pH 8.4, 50 mM KCl, 1.5 mM MgCl 2 , 0.5 mM of each primer, 2.5 U Taq DNA polymerase (Invitrogen, Carlsbad, CA, USA). PCR cycle conditions included denaturation for 30 s at 951C, annealing for 30 s at 551C for COX-2 or 601C for b-actin and extension for 30 s at 721C. Each sample was subjected to PCR at multiple cDNA concentrations for 20-30 cycles to determine the linear range of amplification. The PCR products were compared at the same cDNA concentration and number of cycles within the linear range. Amplification of b-actin was used to normalize COX-2 expression for reverse transcription efficiency and RNA loading.
Abbreviations COX, cyclooxygenase; FBS, fetal bovine serum; FSH, follicle stimulating hormone; HIO cells, human 'immortalized' ovarian surface epithelial cells; IL-1b, interleukin 1-beta; JNK, Jun N-terminal kinase; LH, luteinizing hormone; MAPK (ERK), mitogen-activated protein kinase extracellular-signal regulated kinase; OSE, ovarian surface epithelial; PGH 2 , prostaglandin H 2 ; TNF-a, tumor necrosis factor alpha; TNFR, TNF-a receptor.
Note added in proof
During the review of the manuscript, a recent paper by Gubbay et al (Inflammation-associated gene expression is altered between normal human ovarian surface epithelial cells and cell lines derived from ovarian adenocarcinomas.
Loss of COX-2 expression in ovarian cancer cells W-L Yang et al Br. J. Cancer, 2005 May 23; 92: 1927 -1933 was published. They conclude that ovarian cancer cells fail to responsd to IL1a stimulation for COX-2 induction. The finding is complementary to the conclusion of the current study, suggesting the association of loss of cytokine responsive activity with neoplastic transformation in ovarian epithelial cells.
